Komori
Disclosure4512WAKAMOTO PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Notice Regarding the Recording of a Gain on Sale of Investment Securities (Extraordinary Income)

The Company sold part of 2 listed securities it held, generating a gain on sale of ¥90 million. The gain will be recognized as extraordinary income for the third quarter of the fiscal year ending March 2025.

Worth reading
66In focus
Scored from 4 of 6 sections
Direction
Improvement
Direction inferred from the company’s description.
Scale
90
¥ million
Wording
Definitive
How definitive the wording is.

Decision and Details

Recognition of Gain on Sale of Investment Securities (Extraordinary Income)

Decision2024年12月27日(投資有価証券売却益の発生時期)
Period CoveredThird quarter of the fiscal year ending March 2025
Implementation2024年12月27日(売却実績)
Going forward2025年3月期第3四半期決算において投資有価証券売却益90百万円を特別利益として計上する
Amount投資有価証券売却益:90百万円
Quantity / scale上場有価証券2銘柄
Reason

To improve the efficiency of the Company’s asset holdings

Impact on Business Performance

2025年3月期第3四半期決算において、投資有価証券売却益90百万円を特別利益として計上

Decision and Details
ItemDetails
Matter CoveredRecognition of Gain on Sale of Investment Securities (Extraordinary Income)
Decision Date2024年12月27日(投資有価証券売却益の発生時期)
Implementation Date2024年12月27日(売却実績)
Period CoveredThird quarter of the fiscal year ending March 2025
Amount投資有価証券売却益:90百万円
Quantity / scale上場有価証券2銘柄
Impact on Business Performance2025年3月期第3四半期決算において、投資有価証券売却益90百万円を特別利益として計上
ReasonTo improve the efficiency of the Company’s asset holdings
Future plans2025年3月期第3四半期決算において投資有価証券売却益90百万円を特別利益として計上する
Items this document does not state (3)
Decision-Making BodyGoverning RuleRelated previous disclosures

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To improve the efficiency of our asset holdings.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Recording of a Gain on Sale of Investment Securities (Extraordinary Income) | WAKAMOTO PHARMACEUTICAL CO.,LTD. (4512) timely disclosure | Komori